STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer ; volume:8 ; number:1 ; day:6 ; month:9 ; year:2022 ; pages:1-6 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (6.9.2022), 1-6, 12.2022
- Creator
-
Pantelidou, Constantia
Jadhav, Heta
Kothari, Aditi
Liu, Renyan
Wulf, Gerburg M.
Guerriero, Jennifer L.
Shapiro, Geoffrey I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00471-5
- URN
-
urn:nbn:de:101:1-2022112321201973813538
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pantelidou, Constantia
- Jadhav, Heta
- Kothari, Aditi
- Liu, Renyan
- Wulf, Gerburg M.
- Guerriero, Jennifer L.
- Shapiro, Geoffrey I.
- SpringerLink (Online service)
Other Objects (12)
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
PTK2B promotes TBK1 and STING oligomerization and enhances the STING-TBK1 signaling
ZC3HAV1 facilitates STING activation and enhances inflammation
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
PTK2B promotes TBK1 and STING oligomerization and enhances the STING-TBK1 signaling
ZC3HAV1 facilitates STING activation and enhances inflammation
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
PTK2B promotes TBK1 and STING oligomerization and enhances the STING-TBK1 signaling
ZC3HAV1 facilitates STING activation and enhances inflammation
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma